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Abstract
Background: Methadone maintenance treatment (MMT) was implemented in China since 2004. It was initiated in 8
pilot clinics and subsequently expanded to 738 clinics by the end of 2011. Numerous individual research studies
have been conducted to estimate HIV and HCV prevalence among MMT clients but an overview of the epidemics
in relations to MMT remains unclear. The aim of this study is to estimate the magnitude and changing trends of
HIV, HCV and HIV-HCV co-infections among entry clients to MMT clinics in China during 2004-2010.
Methods: Chinese and English databases of literature were searched for studies reporting HIV, HCV and
co-infection prevalence among MMT clients in China from 2004 to 2010. The prevalence estimates were
summarized through a systematic review and meta-analysis of published literatures.
Results: Ninety eligible articles were selected in this review (2 in English and 88 in Chinese). Nationally, pooled
prevalence of HIV-HCV and HIV-HCV co-infection among MMT clients was 6.0% (95%CI: 4.7%-7.7%), 60.1% (95%CI:
52.8%-67.0%) and 4.6% (95%CI: 2.9%-7.2%), respectively. No significant temporal trend was found in pooled
prevalence estimates. Study location is the major contributor of heterogeneities of both HIV and HCV prevalence
among drug users in MMT.
Conclusions: There was no significant temporal trend in HIV and HCV prevalence among clients in MMT during
2004–2010. Prevalence of HCV is markedly higher than prevalence of HIV among MMT clients. It is recommended
that health educational programs in China promote the earlier initiation and wider coverage of MMT among
injecting drug users (IDUs), especially HIV-infected IDUs.
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Background
Since the implementation of open-door policies in 1979,
illicit drug trade has re-emerged in China. As the most
populous country in the world, China has observed a
rapid increase in drug use over the past three decades
[1]. The number of officially registered drug users
increased from 70,000 in 1990 to 1.33 million at the end
of 2009 [2]. Moreover, behind each registered drug user,
there were estimated 2–4 implicit drug users [3]. Official
statistics indicates that 73.2% of drug users in China in
2009 used heroin [2]. Intravenous injection is the most
common mean of drug use, with injecting drug users
(IDUs) accounting for 59–85% of drug users [4-10].
Drug users (DUs), especially IDUs, represent a high-
risk population for spreading HIV infection due to their
high frequency of injection, sharing of contaminated
needles and other risk behaviours [11-15]. The first do-
mestic Chinese HIV/AIDS cases were found among her-
oin users in Yunnan Province as early as 1989 [16]. By
the end of 2002, HIV cases among drug users were
reported in all 31 Chinese provinces, autonomous
regions and municipalities [4]. The cumulative number
of diagnosed HIV/AIDS cases in China is now well over
200,000, among which over 60% were drug users [6,17].
IDUs account for over 40% of new HIV infections [6,17].* Correspondence: lzhang@kirby.unsw.edu.au
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In China, HIV prevalence has wide geographic varia-
tions. According to the Chinese national surveillance re-
port for 1995–2009 [18], five provinces (Yunnan,
Guizhou, Sichuan, Guangxi and Xinjiang) were classified
as high transmission areas (HTAs) for HIV infection
among drug users, and the rest of country was consid-
ered as low transmission areas (LTAs). HIV prevalence
among drug users in Yunnan and Xinjiang were the
highest among all Chinese provinces, of approximately
25%-30% in 2007 [18,19]. Similarly, HCV prevalence
among DUs in China is high, but estimates vary substan-
tially from 15.6% to 98.7% [20-23].
Harm reduction programs for drug users began in
2003 in China and it is believed that they have contribu-
ted to reductions in the spread of HIV [24-26]. A major
component of this program is methadone maintenance
treatment (MMT), which was initiated as a pilot pro-
gram in 8 clinics serving 1,029 drug users in 2004 and
subsequently expanded to 738 clinics serving 344,254
drug users by the end of 2011, which accounts for ap-
proximately 30% of registered IDUs in China (personal
communication with China CDC). Initially, strict enrol-
ment criteria were imposed to enroll only registered
drug users [27]. In July 2006, new implementation proto-
col of the community-based MMT program has been
announced by the Chinese Ministry of Health to cover a
wider group of drug users [28]. The new protocol recom-
mended MMTclinics also offer ancillary services including
counseling and psychosocial support, testing for HIV and
infections, referrals for antiretroviral treatment and other
social supports [27].
There have been numerous independent studies docu-
menting the prevalence of HIV or HCV among MMT cli-
ents at baseline of their treatment. Across these studies,
large variations in HIV and HCV prevalence estimates
were commonly observed, reflecting the complex geo-
graphical and chronological overlapping of the two epi-
demics. Numerous individual research studies have been
conducted to estimate HIV and HCV prevalence among
MMT clients in China. The studies vary in time and geo-
graphical locations, and do not provide a complete over-
view of HIV and HCV epidemics in relations to MMT in
China. This study aims to investigate the geographical and
the temporal patterns of HIV and HCV epidemics in
China and their likely interaction. We do this through a
systematic review and meta-analysis and we also discuss
implications for future MMT implementation and health
policies for HIV prevention among IDUs in China.
Methods
Search strategy
Two independent investigators conducted a systematic
review of published peer-reviewed research articles by
searching the following databases: PubMed, Chinese
Scientific Journals Fulltext Database (CQVIP), China
National Knowledge Infrastructure (CNKI) and Wanfang
Data from 2004–2010. Keywords used in the database
search included (“Methadone” OR “Methadone Mainten-
ance Treatment” OR “Methadone Maintenance Therapy”
OR “Methadone Maintenance”) AND (“HIV” OR “AIDS”
OR “HCV” OR “hepatitis C virus” OR “co-infection”)
AND (“China” OR “China Mainland”). We also per-
formed a manual search of the reference lists of pub-
lished articles. This review was conducted and reported
according to the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) Statement
issued in 2009 [29].
Study selection
Studies were eligible for inclusion in this systematic review
if they met the following criteria: (1) study published in
Chinese or English language; (2) study reported HIV or
HCV prevalence estimates among clients in MMTat base-
line of treatment in China; (3) HIV and HCV infection
must be diagnosed from laboratory serologic testing; (4)
study design such as study site, time period and sample
size must be reported. Intervention studies among MMT
clients were also included. Exclusion criteria were: (1) re-
view papers; (2) non peer–reviewed local/government
reports; (3) conference abstracts and presentations; (4)
self-reported HIV or HCV infections; (5) dissertations. If
the same study data were published in both English and
Chinese sources, the articles published in Chinese lan-
guage were excluded from this study.
Validity assessment
The quality of studies was assessed using a validated
quality assessment tool for cross-sectional studies [30].
The following eight items were assessed to calculate a
total quality score: (1) clear definition of the target
population; (2) representativeness of probability sam-
pling; (3) sample characteristics matching the overall
population; (4) adequate response rate; (5) standardized
data collection methods; (6) reliable of survey measures/
instruments; (7) valid of survey measures/instruments;
(8) appropriate statistical methods. Answers were scored
0 and 1 for ‘No’ and ‘Yes’, respectively. The total quality
score varied between 0 and 8 for each study.
Data abstraction
We extracted the following information from all eligible
studies: published year, study site, study period, gender,
age, marital status, education, study design, clients re-
cruitment methods, sample size; laboratory test methods
for HIV and HCV, prevalence of HIV, HCV and HIV-
HCV co-infection among MMT clients at the baseline of
the treatment. The studies were then categorized by geo-
graphical locations according to their level of HIV
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transmission, and also into two specific time periods,
prior to and after 2006.
Statistical analysis
Meta-analyses were carried out with the Comprehensive
Meta-Analysis software (V2.0, Biostat, Englewood, New
Jersey). The effect rates of pooled prevalence estimates
and 95% confidence intervals (CI) were determined based
on random effect models. Random effect models were ap-
plied when heterogeneity across subgroups were found to
be significant. Heterogeneity tests were performed using
the Cochran Q-test (p< 0.10 represents statistically sig-
nificant heterogeneity) and I2 statistic. We investigated the
factors that are associated with heterogeneities in the
stratified meta-analyses using meta-regression. Meta-
regression was performed in STATA 10.0 (StataCrop,
Texas, USA) Potential publication bias was measured by
the Begg and Mazumdar rank correlation (p< 0.05).
Spearmen correlation was used to assess the relationship
between HIV prevalence and HCV prevalence among cli-
ents in MMT in China.
Results
Trial flow/flow of included studies
A total of 834 studies were identified from four elec-
tronic databases (62 in PubMed, 410 in CNKI, 144 in
CQVIP, 218 in Wanfang database). Due to duplication
and irrelevance, we excluded 478 articles after screening
the titles. We screened the abstracts of the remaining
356 articles, following which 216 articles were excluded
Figure 1 Flow chart showing the meta-analysis studies selection. N; the number of articles included in systematic review; n, the number of
prevalence estimates included in meta-analysis.
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Table 1 Summary of HIV prevalence among clients in MMT in China










HTAs Guangxi 3 17.7% (7.2-37.4%) 17.5% (14.0-21.6%)
Zhou XP, 2009 [31] 2007 28.2% (22.0-35.5%)
Chang ZR, 2010 [32] 2008 27.9% (25.2-30.7%)
Bai Y, 2009 [33] 2009 6.0% (4.2-8.4%)
Guizhou 4 20.7% (14.2-29.2%)
Chang ZR, 2010 [32] 2008 24.6% (21.5-28.1%)
Han XJ, 2010 [34] 2009 27.0% (22.3-32.2%)
Li XY, 2009 [35] 2009 0.5% (0.1-3.5%)
Wang J, 2010 [36] 2009 20.3% (14.5-27.7%)
Sichuan 8 7.1% (3.8-12.9%)
Hao C, 2006 [37] 2004 13.6% (10.4-17.6%)
Qian HZ, 2007 [38] 2005 14.0% (11.4-17.1%)
Chen B, 2009 [39] 2006 2.0% (1.0-3.9%)
Liu JK, 2009 [40] 2006 14.1% (8.2-23.2%)
Dong G, 2009 [41] 2007 4.3% (2.6-7.0%)
Wang Y, 2009 [42] 2008 3.8% (2.6-5.5%)
Wang DY, 2009 [43] 2008 21.7% (18.9-24.9%)
Yao W, 2008 [44] 2008 2.3% (1.4-3.6%)
Xinjiang 6 22.0% (15.2-30.6%)
Liu JB, 2006 [45] 2005 19.4% (13.4-27.1%)
Fu LP, 2007 [46] 2006 33.4% (29.7-37.3%)
Fang HR, 2008 [47] 2008 14.2% (12.6-16.1%)
Re ZW, 2009 [48] 2008 28.6% (22.4-35.7%)
Shen L, 2009 [49] 2008 14.9% (12.8-17.3%)
Yuan L, 2010 [50] 2008 26.55(20.8-33.0%)
Yunnan 6 36.0% (25.6-47.9%)
Duan YJ, 2008 [51] 2006 33.3% (24.8-43.2%)
Zhang MJ, 2008 [52] 2007 51.8% (44.2-59.3%)
Zhuang HY, 2008 [53] 2007 66.7% (51.8-78.8%)
Xue HM, 2010 [54] 2008 39.3% (37.1-41.5%)
Yang GW, 2010 [55] 2008 15.7% (11.4-21.3%)
Yang YC, 2011 [56] 2009 23.1% (21.7-24.5%)
LTAs Beijing 1 4.6% (2.7-7.8%) 2.4% (1.6-3.5%)
Du WJ, 2007 [57] 2005 4.6% (2.7-7.8%)
Chongqing 3 6.8% (4.3-10.6%)
Tan XL, 2007 [58] 2005 7.8% (5.5-11.0%)
Wu GH, 2010 [59] 2007 9.2% (7.1-11.8%)
Zhou X, 2009 [60] 2008 4.3% (3.0-6.1%)
Fujian 2 2.1% (1.1-3.9%)
Wu LH, 2007 [61] 2006 2.0% (0.5-7.6%)
Zheng WX, 2009 [62] 2006 2.1% (1.0-4.3%)
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Table 1 Summary of HIV prevalence among clients in MMT in China (Continued)
Gansu 2 0.7% (0.3-1.5%)
Gao LF, 2010 [63] 2009 0.8% (0.2-3.2%)
Zhu XH, 2010 [64] 2010 0.7% (0.2-1.7%)
Guangdong 13 3.6% (1.6-8.3%)
Dai LP, 2009 [65] 2007 5.9% (2.7-12.6%)
Liu XY, 2009 [66] 2007 1.2% (1.0-1.5%)
Zhang QL, 2008 [67] 2007 0.2% (0.0-3.8%)
Chen W, 2009 [68] 2008 20.7% (17.2-24.7%)
Chen A, 2007 [69] 2008 19.6% (16.4-23.3%)
Dai LP, 2010 [70] 2008 3.5% (1.8-6.6%)
Hu WS, 2010 [71] 2008 9.6% (5.5-16.1%)
Li LY, 2009 [72] 2008 1.0% (0.1-6.8%)
Li YF, 2009 [73] 2008 2.5% (1.0-5.9%)
Wang M, 2009 [74] 2008 1.3% (0.1-17.5%)
Wang CQ, 2009 [75] 2009 1.9% (1.0-3.8%)
Wu ZL, 2010 [76] 2009 7.9% (5.8-10.6%)
Xia L, 2010 [77] 2009 1.2% (0.4-3.7%)
Henan 1 0.9% (0.2-3.6%)
Wu SX, 2009 [78] 2008 0.9% (0.2-3.6%)
Hubei 1 0.1% (0.0-1.8%)
Qiu XQ, 2009 [79] 2006 0.1% (0.0-1.8%)
Hunan 7 6.9% (4.1-11.4%)
Li XL, 2008 [80] 2006 1.2% (0.3-4.7%)
Li XL, 2009 [81] 2006 16.7% (14.2-19.7%)
Tang XY, 2007 [82] 2006 14.7% (10.2-20.7%)
Chen LF, 2009 [83] 2007 13.7% (10.3-18.1%)
He HX, 2008 [84] 2007 9.5% (7.5-12.0%)
Chen C, 2010 [85] 2008 1.9% (0.5-7.2%)
Feng YH, 2010 [86] 2009 0.6% (0.2-1.8%)
Jiangsu 6 0.9% (0.5-1.5%)
Wang YP, 2009 [87] 2007 1.4% (0.5-4.3%)
Feng SQ, 2010 [88] 2008 1.1% (0.4-2.8%)
Hao C, 2009 [89] 2008 0.6% (0.2-1.6%)
Xu GY, 2008 [90] 2008 0.5% (0.0-7.3%)
Zhang MH, 2010 [91] 2008 1.0% (0.3-3.0%)
Yuan ZX, 2010 [92] 2009 0.2% (0.0-3.4%)
Ningxia 1 1.2% (0.5-2.6%)
Jiang A, 2009 [93] 2007 1.2% (0.5-2.6%)
Qinghai 1 1.4% (0.5-3.8%)
Hao XQ, 2009 [94] 2008 1.4% (0.5-3.8%)
Shaanxi 2 1.4% (0.5-3.8%)
Jia W, 2008 [95] 2006 1.7% (0.7-3.9%)
Zhang HF, 2009 [96] 2008 0.4% (0.0-6.3%)
Shanghai 2 1.4% (0.5-4.8%)
Liu Y, 2009 [97] 2008 1.5% (0.5-4.4%)
Li T, 2010 [98] 2009 1.0% (0.1-13.6%)
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(147 were not relevant, 25 were dissertations, 22 were
non peer-reviewed theses, 10 were conference presenta-
tions or abstracts, 7 were reviews or letters and 5 were
not carried out in mainland China). Among the
remaining 140 articles eligible for full-text screening; we
further excluded 50 articles (32 were not conducted
among MMT clients, 5 did not report original data, 5
reported results from already identified data sources, 3
did not report study sites, 3 did not report study period,
2 studies covered multiple provinces). We finally
included 90 articles (2 in English and 88 in Chinese) for
subsequent quantitative synthesis, of which, 72, 71 and
19 articles were eligible for meta-analysis of HIV, HCV
and HIV-HCV co-infection prevalence, respectively. The
selection process is illustrated in Figure 1 and the quality
score of each study is shown in the Additional file 1:
Table S1.
Study characteristics
The 90 eligible articles were from 19 of the 31 Chinese
provinces. The sample size of the selected studies ranged
from 38 to 8662 (median: 300; IQR: 175–512). All parti-
cipants were recruited from MMT clinics. Eighty-one
out of 90 studies (90%) were cross-sectional, 5 (6%) were
cohort studies, 2 (2%) were randomized controlled trials
and 2 (2%) did not report the study design. There were
72, 71 and 19 prevalence estimates on HIV, HCV and
HIV-HCV co-infection among MMT clients at baseline
of treatment respectively.
Epidemic trends of HIV, HCV infection and HIV-HCV
co-infection
The overall national prevalence of HIV, HCV and HIV-
HCV co-infection among MMT clients at baseline of
treatment in China were 6.0% (95% CI: 4.7-7.7%), 60.1%
(95% CI: 52.8-67.0%) and 4.6% (95% CI: 2.9-7.2%) re-
spectively. Prevalence in HTAs were consistently higher
than those in LTAs (HIV: 17.5% (95% CI: 14.0-21.6%) vs.
2.4% (95% CI: 1.6-3.5%); HCV: 70.2% (95% CI: 62.6-
76.8%) vs. 55.5% (95% CI: 46.4-64.2%); HIV-HCV co-
infection: 8.0% (95% CI: 4.8-12.9%) vs. 2.5% (95% CI:
1.4-4.4%)). Large variations in prevalence were also
observed geographically. Whereas HIV prevalence
among MMT clients varied from 0.1% (Hubei) to 36.0%
(Yunnan) (Table 1, Figure 2a), HCV prevalence varied
from 10.9% (Henan) to 65.7% (Guangxi) (Table 2,
Figure 2b) and HIV-HCV co-infection varied from 0.5%
(Henan) to 12.6% (Guangxi) (Table 3, Figure 2c). The
forest plots showing the results of meta-analysis of HIV,
HCV and HIV-HCV co-infection prevalence among cli-
ents in MMT are illustrated in the Additional file 1:
Figure S1, S2 and S3. However, no temporal trends of
any of these infections were found at the national level,
in HTAs or LTAs since the initiation of MMT in 2004.
Our analysis reported high heterogeneities across the
collected studies in evaluation of the pooled prevalence of
the infections (HIV: I2 = 97.614, p< 0.001; HCV:
I2 = 99.163, p< 0.001; HIV-HCV: I2 = 96.671; p< 0.001).
For HIV and HCV infections, meta-regression demon-
strated that these heterogeneities were mainly contributed
by the geographical locations of the studies and contribu-
tions from study language, sample size, sampling method
and study time period were not significant. In contrast,
studies with sampling sizes greater than 500 tended to re-
port higher HIV-HCV co-infection rates than otherwise
and the influence of geographical location was marginal
(Table 4). No publication bias was found across the 72, 71
and 19 studies reported HIV, HCV and HIV-HCV co-
infection (Begg rank correlation analysis p= 0.163, 0.702
and 0.649, respectively). A significantly positive correlation
(Spearman, r= 0.456, p< 0.001) was observed between
HIV and HCV prevalence among clients in Chinese MMT
during 2004–2010 countrywide.
Discussion
Consistent with findings from national sentinel surveil-
lance [18], our meta-analyses indicated that HIV and
HCV prevalence in MMT is distinctly higher in HTAs.
This confirms that the prevalence of these infections
remained highly concentrated among provinces along
the traditional drug-trafficking routes but are consider-
ably lower in the rest of the country.
Our estimated national HIV prevalence of 6.0% (95%
CI: 4.7-7.7%) among people in MMT is not significantly
different to the estimated HIV prevalence among non-
MMT drug users (4.6-7.5%) reported by national senti-
nel surveillance during 2004–2009 [18]. We noticed that
HIV prevalence among people in MMT in Sichuan
(7.1%) and Guizhou (20.7%) province is higher than that
from sentinel surveillance data [2,27,121-123], indicating
that methadone clinics in these areas may have recruited
more HIV-positive patients among drug users [124].
Table 1 Summary of HIV prevalence among clients in MMT in China (Continued)
Zhejiang 3 0.5% (0.1-1.6%)
Cai CP, 2008 [99] 2007 0.6% (0.0-8.4%)
Zhang XH, 2008 [100] 2007 0.6% (0.1-4.2%)
Su MF, 2010 [101] 2009 0.3% (0.0-2.3%)
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Additionally, our stratified time analysis of HIV, HCV
and HIV-HCV co-infection among MMT clients did not
show significant temporal trends in the prevalence of
these infections since initiation of MMT in 2004. This
suggested that the 2006 national policy to relax the eligi-
bility criteria for MMT enrollment was not sufficient to
encourage more HIV-infected drug users to participate
in the program. MMT is known to significantly reduce
the consumption of heroin and associated risk beha-
viours of the participants [24,125-129]. It is therefore in
the best interest of the Chinese government to substan-
tially scale-up the proportion of HIV-infected partici-
pants in MMT. The consequent reduction in risk
behaviours of the infected population may help to con-
fine the transmission sources of HIV infection. In order
to achieve this, more comprehensive services, such as
referral services, counseling, social supports targeting
HIV-infected drug users etc., should be provided. Educa-
tional programs to reduce social stigma as well as psy-
chological barriers for treatment adherence especially for
HIV-infected drug users should be implemented.
Our analysis indicated a national HCV prevalence of
59.9% (95% CI: 52.7-66.7%) among MMT clients in
China. This result is higher than the reported prevalence
of 50.4% (95% CI: 42.5-58.4%) in a recent meta-analysis
[130], in which the subjects were selected not only from
MMT, but also from detoxification centers and the com-
munity. Chinese sentinel surveillance did not start moni-
toring HCV among drug users until 2009 and there have
been no data currently published. Consistent with find-
ings in other settings, HCV prevalence is positively cor-
related with HIV prevalence among MMT clients in
China [89,130,131]. The fact that HCV prevalence was
found to be 10 times higher than HIV prevalence may
be due to a number of reasons. Biologically, transmission
efficiency of blood-borne HCV has been estimated to be
approximately 10 times greater than that of HIV for
needle-stick injuries [132]. Secondly, HCV infection may
have entered drug users population much earlier and
hence already established a stabilized epidemic in China
[131,133]. With a large number of chronic HCV-infected
individuals in the drug user communities, a susceptible
person may be more prone to the infection through
needle-sharing with other IDUs.
The prevalence of HIV-HCV co-infection and HIV
were not markedly different suggesting that a large pro-
portion of HIV-infected MMT clients in China are also
infected with HCV. Studies have shown that the co-
infection of these diseases interact synergistically and
the presence of each infection can substantially reduce
the immune clearance of the other [134-136]. HCV co-
infection may accelerate the progression to AIDS stage
and death [134], even among people with continuous
suppression of HIV replication [137]. It also blunts the
Figure 2 The regional distribution of pooled prevalence of
(a) HIV infection; (b) HCV infection; and (c) HIV-HCV co-infection
in MMT in China.
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Table 2 Summary of HCV prevalence among clients in MMT in China










HTAs Guangxi 3 87.2% (85.4-88.8%) 70.2% (62.6-76.8%)
Zhou XP, 2009 [31] 2007 88.8% (83.1-92.8%)
Chang ZR, 2010 [32] 2008 87.9% (85.5-89.8%)
Bai Y, 2009 [33] 2009 85.5% (82.2-88.3%)
Guizhou 6 61.5% (46.1-75.0%)
Chang ZR, 2010 [32] 2008 76.1% (72.7-79.3%)
Wang J, 2008 [102] 2008 41.6% (34.6-48.9%)
Deng CK, 2009 [103] 2008 61.4% (55.9-66.7%)
Han XJ, 2010 [34] 2009 60.0% (54.4-65.4%)
Li XY, 2009 [35] 2009 33.5% (27.3-40.4%)
Wang J, 2010 [36] 2009 86.7% (80.1-91.4%)
Sichuan 6 77.4% (71.0-82.8%)
Hao C, 2006 [37] 2004 67.3% (62.2-72.1%)
Qian HZ, 2007 [38] 2005 68.4% (64.4-72.1%)
Dong G, 2009 [41] 2007 78.6% (74.0-82.6%)
Wang DY, 2009 [43] 2008 83.7% (80.7-86.2%)
Yao W, 2008 [44] 2008 82.9% (80.0-85.4%)
Zhao XH, 2009 [104] 2008 80.1% (75.9-83.7%)
Xinjiang 5 64.8% (50.0-77.2%)
Liu JB, 2006 [45] 2005 69.0% (60.5-76.4%)
Fu LP, 2007 [46] 2006 40.0% (36.1-44.0%)
Fang HR, 2008 [47] 2008 68.9% (66.5-71.2%)
Yuan L, 2010 [50] 2008 72.0% (65.4-77.8%)
Re ZW, 2009 [48] 2008 72.0% (64.9-78.2%)
Yunnan 1 23.8% (18.5-30.0%)
Yang GW, 2010 [55] 2008 23.8% (18.5-30.0%)
LTAs Anhui 2 62.3% (17.0-93.0%) 55.5% (46.4-64.2%)
Wang XR, 2007 [105] 2007 36.4% (31.0-42.2%)
Zhan SW, 2008 [106] 2007 82.8% (77.1-87.3%)
Beijing 1 46.4% (40.7-52.3%)
Du WJ, 2007 [57] 2005 46.4% (40.7-52.3%)
Chongqing 2 76.2% (73.6-78.5%)
Zhou X, 2009 [60] 2007 74.7% (71.0-78.1%)
Wu GH, 2010 [59] 2008 77.2% (74.3-79.9%)
Fujian 2 48.4% (26.2-71.1%)
Wu LH, 2007 [61] 2006 36.0% (27.2-45.8%)
Zheng WX, 2009 [62] 2006 60.2% (54.8-65.3%)
Gansu 3 23.7% (18.0-30.7%)
Gao LF, 2010 [63] 2009 23.8% (18.9-29.5%)
He XX, 2010 [107] 2009 19.5% (17.6-21.6%)
Zhu XH, 2010 [64] 2010 28.7% (25.3-32.4%)
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Table 2 Summary of HCV prevalence among clients in MMT in China (Continued)
Guangdong 8 63.7% (25.2-90.1%)
Liu XY, 2009 [66] 2007 5.4% (4.9-5.9%)
Zhang QL, 2008 [67] 2007 30.3% (24.4-37.0%)
Hu WS, 2010 [71] 2008 96.0% (90.7-98.3%)
Li LY, 2009 [72] 2008 67.0% (57.2-75.5%)
Li YF, 2009 [73] 2008 77.0% (70.7-82.3%)
Wang M, 2009 [74] 2008 81.6% (66.1-91.0%)
Wang CQ, 2009 [75] 2009 77.3% (73.0-81.0%)
Xia L, 2010 [77] 2009 62.2% (56.1-68.1%)
Henan 1 10.9% (7.4-15.8%)
Wu SX, 2009 [78] 2008 10.9% (7.4-15.8%)
Hubei 1 94.3% (91.2-96.3%)
Peng JS, 2007 [108] 2006 94.3% (91.2-96.3%)
Hunan 5 66.4% (49.3-80.1%)
Li XL, 2008 [80] 2006 49.4% (41.8-57.0%)
He HX, 2008 [84] 2007 58.3% (54.5-62.0%)
Chen LF, 2009 [83] 2007 59.5% (54.9-63.9%)
Chen C, 2010 [85] 2008 51.4% (42.0-60.7%)
Feng YH, 2010 [86] 2009 93.7% (91.2-95.5%)
Jiangsu 10 61.6% (51.8-70.6%)
Xia X, 2007 [109] 2006 35.0% (32.6-37.6%)
Xu YP, 2007 [110] 2006 61.0% (56.1-65.6%)
Wang YP, 2009 [87] 2007 70.5% (64.0-76.3%)
Feng SQ, 2010 [88] 2008 52.3% (47.2-57.3%)
Hao C, 2009 [89] 2008 51.8% (47.9-55.6%)
Song HB, 2010 [111] 2008 66.2% (59.6-72.2%)
Xu GY, 2008 [90] 2008 76.2% (67.0-83.5%)
Zhang MH, 2010 [91] 2008 75.1% (70.0-79.6%)
Yuan ZX, 2010 [92] 2009 56.5% (50.1-63.0%)
Wang WM, 2010 [112] 2010 68.8% (62.3-74.7%)
Ningxia 2 23.0% (16.7-30.9%)
Jiang A, 2009 [93] 2007 20.3% (17.0-24.0%)
Liu XP, 2010 [113] 2009 28.0% (19.8-37.9%)
Qinghai 1 70.8% (65.1-75.8%)
Hao XQ, 2009 [94] 2008 70.8% (65.1-75.8%)
Shaanxi 55.3% (43.2-66.7%)
Jia W, 2008 [95] 5 2006 54.0% (48.3-59.6%)
Li YC, 2009 [114] 2008 60.6% (55.8-65.3%)
Zhang HF, 2009 [96] 2008 40.0% (31.6-49.0%)
Zang JF, 2010 [115] 2009 42.6% (30.9-55.2%)
Liu HB, 2010 [116] 2010 73.8% (69.7-77.5%)
Shanghai 2 59.7% (54.2-64.9%)
Liu Y, 2009 [97] 2008 61.2% (54.3-67.6%)
Du J, 2009 [117] 2009 57.0% (47.8-65.8%)
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CD4+ cell increase in HIV-infected people receiving
antiretroviral therapy [137]. It is therefore a high priority
to provide necessary healthcare and treatment for co-
infected individuals in parallel to the roll-out of MMT in
China.
Several limitations in this study should be noted. First,
by the end of November 2010, there were 696 MMT
clinics in China, covering 27 Chinese provinces [138],
however, out of these, eight provinces did not publish
any reports on the prevalence of HIV or HCV. Further-
more, estimates of HIV or HCV prevalence from Beijing,
Henan, Hebei, Ningxia and Qinghai provinces were
based on only one report. These may likely contribute to
bias of the overall regional or national prevalence.
Table 2 Summary of HCV prevalence among clients in MMT in China (Continued)
Zhejiang 5 40.1% (24.7-57.8%)
Zhang XH, 2007 [118] 2006 28.9% (16.8-45.1%)
Cai CP, 2008 [99] 2007 75.9% (65.8-83.7%)
Zhang XH, 2008 [110] 2007 40.6% (33.4-48.3%)
Fu YF, 2009 [119] 2008 40.4% (35.4-45.6%)
Su MF, 2010 [101] 2009 18.9% (14.8-23.7%)
Table 3 Summary of HIV-HCV Co-infection among clients in MMT in China










HTAs Guangxi 3 12.6% (4.0-33.4%) 8.0% (4.8-12.9%)
Zhou XP, 2009 [31] 2007 11.2% (7.2-16.9%)
Chang ZR, 2010 [32] 2008 27.4% (24.7-30.2%)
Bai Y, 2009 [33] 2009 5.8% (4.1-8.2%)
Guizhou 3 3.8% (0.4-29.3%)
Chang ZR, 2010 [32] 2008 23.1% (20.0-26.5%)
Wang J, 2010 [36] 2009 0.7% (0.1-4.8%)
Han XJ, 2010 [34] 2009 2.0% (0.9-4.4%)
Sichuan 4 6.8% (2.8-15.8%)
Qian HZ, 2007 [38] 2005 13.5% (10.9-16.6%)
Dong G, 2009 [41] 2007 3.4% (2.0-5.9%)
Wang DY, 2010 [120] 2008 19.2% (16.4-22.3%)
Yao W, 2008 [44] 2008 1.9% (1.1-3.2%)
LTAs Chongqing 2 5.3% (1.9-13.9%) 2.5% (1.4-4.4%)
Zhou X, 2009 [60] 2007 8.7% (6.6-11.2%)
Wu GH, 2010 [59] 2008 3.1% (2.1-4.5%)
Fujian 1 1.0% (0.1-6.8%)
Wu LH, 2007 [61] 2006 1.0% (0.1-6.8%)
Gansu 1 0.8% (0.2-3.2%)
Gao LF, 2010 [63] 2009 0.8% (0.2-3.2%)
Guangdong 2 1.9% (0.9-3.8%)
Li YF, 2009 [72] 2008 2.5% (1.0-5.9%)
Xia L, 2010 [77] 2009 1.2% (0.4-3.7%)
Henan 1 0.5% (0.1-3.2%)
Wu SX, 2009 [78] 2008 0.5% (0.1-3.2%)
Hunan 1 6.8% (4.8-9.4%)
Chen LF, 2009 [83] 2009 6.8% (4.8-9.4%)
Jiangsu 1 1.0% (0.2-3.7%)
Wang YP, 2009 [87] 2007 1.0% (0.2-3.7%)
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Further investigations in more cities are necessary to
provide a more accurate description of HIV and HCV
epidemics. Second, our study was focused on HIV and
HCV infections among the same study cohorts, studies
reporting only HIV or HCV prevalence estimates were
excluded in this review and hence some significant stud-
ies might be missing in the stratified meta-analyses.
Third, there are also a potentially large number of gov-
ernmental documents, community-level reports and
other unpublished data that have never been archived in
any of the public literature databases. Fourth, we identi-
fied that the presence of high heterogeneities may be at-
tributable to demographical differences in HIV and HCV
prevalence among MMT clients across different Chinese
geographical regions, but not the language of article,
sampling method and study time may not explain the
variations observed. It is important to note that other
unreported factors, such as age, socio-economic status
and sexual behaviours, may also be contributable to the
heterogeneities.
Conclusions
Our study has several important implications to the fu-
ture implementation of MMT in China. First, despite a
rapid and substantial expansion of MMT program
coverage in China [124,139] the proportion of HIV- and
HCV-infected drug users attending MMT remains low.
Although MMT is beneficial at an individual-level, it can
potentially be an effective population-level intervention
strategy. Future expansion of MMT should target the
infected population, as only inclusion of a large propor-
tion of these infected individuals may substantially re-
duce their risk behaviours and maximize the preventive
effects of MMT at a population level. Second, MMT
should not be viewed as a replacement for other harm
reduction programs, such as, needle and syringe
exchange programs (NSEPs). A previous study has
demonstrated that NSEPs in China are both effective
and cost-effective for HIV prevention [3]. MMT should
be rolled-out in conjunction with NSEPs to reduce the
number of new infections. Third, as a result of high per-
centage of HCV co-infection among HIV-infected MMT
clients at baseline of the treatment, other programs that
providing treatment to HIV and HCV infected patients
should also be provided to MMT clients. Fourth, the
greater risk of IDUs being infected with HIV and HCV
and reported relapse to drug usage may be a contribut-
ing factor to low retention in MMT [140,141]. It is
therefore important for MMT to ensure sufficient sup-
port and care is provided for enrolled IDUs to maintain
their behavioural changes. Peer-group support and fre-
quent counseling follow-ups may be beneficial in build-
ing motivating environment for abstinence from
addictions.
Table 4 Result of individual variable meta-regression models for each stratified meta-analysis
Stratified meta-analyses
Study Characteristic HIV prevalence HCV prevalence HIV-HCV co-infection prevalence
Pooled estimate Meta-regression Pooled estimate Meta-regression Pooled estimate Meta-regression
% (95% CI), n (β, p-value) % (95% CI), n (β, p-value) % (95% CI), n (β, p-value)
Language of article:
Chinese 6.0 (4.7-7.6), n = 70 0.060 60.1 (52.6-67.2), n = 69 0.018 4.2 (2.5-6.8), n = 18 0.402
English 8.4 (2.7-23.0), n = 2 p = 0.956 57.9 (35.9-77.1), n = 2 p = 0.964 13.5 (10.9-16.6), n = 1 p = 0.823
Sample size:
<500 4.8 (3.4-6.7), n = 50 0.178 59.8 (54.6-64.9), n = 53 −0.189 2.2 (1.2-4.1), n = 11 1.367
≥500 8.2 (5.6-11.8), n = 22 p = 0.561 60.3 (42.3-75.8), n = 18 p = 0.191 9.8 (5.7-16.2), n = 8 p = 0.029
Study locations*:
HTA 17.5 (14.0-21.6), n = 27 −1.811 70.2 (62.6-76.8), n = 21 −0.335 8.0 (4.8-12.9), n = 10 −0.831
LTA 2.4 (1.6-3.5), n = 45 p< 0.001 55.5 (46.4-64.2), n = 50 p = 0.017 2.5 (1.4-4.4), n = 9 p = 0.139
Sampling method:
Cross-sectional 5.7 (4.3-7.4), n = 580 0.148 62.4 (54.2-69.9), n = 60 −0.275 4.6 (2.9-7.2), n = 19 -
Others 8.3 (5.1-13.2), n = 14 p = 0.686 46.2 (36.3-56.5), n = 11 p = 0.112 - -
Time period:
2004–2006 8.0 (5.2-12.2), n = 16 −0.268 56.7 (47.0-65.8), n = 13 0.026 4.5 (0.3-40.4), n = 2 0.353
2007–2010 5.5 (4.1-7.3), n = 56 p = 0.458 60.9 (52.1-69.0), n = 58 p = 0.879 4.4 (2.7-7.2), n = 17 p = 0.803
Table showing the pool estimate (%), 95% confidence interval (CI), number of studies (n), meta-regression coefficient (β) and significance of β (p-value). p-values
in bold print represent significant associations (p< 0.10).
* Study locations were categorized into two regions. HTA (high HIV transmission areas among DUs): Yunnan, Guizhou, Sichuan, Guangxi and Xinjiang; LTA (low
HIV transmission areas among DUs): all provinces except above in Chinese mainland.
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